Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Repligen (NASDAQ:RGEN), a bioprocessing technology leader in life sciences, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 13-16 in San Francisco. Olivier Loeillot, President and CEO, will deliver a company overview presentation on Tuesday, January 14 at 1:30 p.m. PT.

The presentation will be accessible via live webcast through Repligen's Investor Relations website at www.repligen.com. A replay option will be available for a time after the event.

News Market Reaction – RGEN

-0.35%

-0.35% Session move

In the trading session that priced this news, RGEN declined 0.35%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the 43^rd Annual J.P. Morgan Healthcare Conference, being held January 13 – 16 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 14 at 1:30 p.m. PT.

A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about our company see our website at www.repligen.com, and follow us on LinkedIn.

Repligen Contact:
Sondra S. Newman
VP, Global Head of Investor Relations
(781) 419-1881
investors@repligen.com

FAQ

When is Repligen (RGEN) presenting at the 2025 J.P. Morgan Healthcare Conference?

Repligen (RGEN) is scheduled to present on Tuesday, January 14, 2025, at 1:30 p.m. PT during the 43rd Annual J.P. Morgan Healthcare Conference.

How can investors watch Repligen's (RGEN) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation via live webcast through Repligen's Investor Relations website at www.repligen.com. A replay will be available for a time after the event.

What is the duration of the 2025 J.P. Morgan Healthcare Conference where RGEN is presenting?

The 43rd Annual J.P. Morgan Healthcare Conference runs from January 13 to January 16, 2025, in San Francisco.

Who will be presenting for Repligen (RGEN) at the 2025 J.P. Morgan Healthcare Conference?

Olivier Loeillot, President and Chief Executive Officer of Repligen, will present the company overview at the conference.